Semaglutide is a GLP-1 receptor agonist extensively studied for its effects on appetite regulation, glucose metabolism, body weight, and broader cardiometabolic pathways. FDA-approved semaglutide medicines have established clinical indications, but research-labeled material should not be represented as an approved drug product. For research purposes only.
Semaglutide is a GLP-1 receptor agonist extensively studied for its effects on appetite regulation, glucose metabolism, body weight, and broader cardiometabolic pathways. FDA-approved semaglutide medicines have established clinical indications, but research-labeled material should not be represented as an approved drug product. For research purposes only.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
on orders over $200
plain and unbranded packaging
256-bit SSL
Not a researcher? Exit
